

Synthesis and biological evaluations of new families of histidine kinases inhibitors

Valentin Duvauchelle, Miyanou Rosales-Hurtado, Thibaut Boibessot, David Bénimèlis, Catherine Dunyach-Remy, Jean Philippe Lavigne, Hendrik Szurmant, Patrick Meffre, Zohra Benfodda

▶ To cite this version:

Valentin Duvauchelle, Miyanou Rosales-Hurtado, Thibaut Boibessot, David Bénimèlis, Catherine Dunyach-Remy, et al.. Synthesis and biological evaluations of new families of histidine kinases inhibitors. GSO-JMJC-JED2019, Oct 2019, Montpellier, France. . hal-02333120

HAL Id: hal-02333120

https://hal.science/hal-02333120

Submitted on 28 Oct 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



SYNTHESIS AND BIOLOGICAL EVALUATIONS OF NEW FAMILIES OF HISTIDINE KINASES INHIBITORS



Valentin DUVAUCHELLE,¹ Miyanou ROSALES-HURTADO,¹ Thibaut BOIBESSOT,¹ David BENIMELIS,¹ Catherine DUNYACH-REMY,³ Jean-Philippe LAVIGNE,³ Hendrik SZURMANT,² Patrick MEFFRE¹ and Zohra BENFODDA.¹

¹UNIV. NIMES, EA7352 CHROME, Rue du Dr G. Salan, 30021 Nîmes cedex 1, France ²College of Osteopathic Medicine of the Pacific, Western University of health Sciences, Pomona, CA 91766, USA ³Institut National de la Santé et de la Recherche Médicale, U1047, Montpellier University, CHU de Nîmes, Place du Pr R. Debré, 30029 Nîmes, France

I. INTRODUCTION

Nowadays, the emergence of multidrug resistant bacteria requires interest in the medical field and thereby an urgent need to develop efficient and specific methods in targeting unique bacterial cellular processes. 1,2 Two-component signal transduction systems (TCS) are widely used in bacteria to allow adaptation, osmosis and resistance appearance by translating an external signal into a cellular response. In order to attenuate these signaling pathways, we aimed at targeting the TCS signal transducer histidine kinase by focusing on their highly conserved ATP-binding domain.³ Preliminary modeling work carried out in our laboratory led to a series of thiophene derivatives. Twenty-one new thiophene derivatives were synthesized and evaluated in vitro on bacterial histidine kinases (HK) PhoR, ResE and WalK, from which eight derivatives showed significant inhibitory activity. One compound exhibited broad-spectrum antimicrobial activity with the particularity to restore antibacterial activity of antibiotics ineffective on resistant bacteria treated alone,⁴ With the purpose to improve biological activity, amino thiophene derivatives have been developed.

II. SYNTHESIS

$$R'$$
 R_1
 R_2
 R_3

6a-6g X = S; $R' = NO_2$ **7a-7g** X = S; $R' = CH_3CO$ **8a-8g** X = S; $R' = NHCOCH_3$ $9d-9g X = O ; R' = NO_2$

III. BIOLOGICAL EVALUATIONS

Evaluations have been realized on other proteins of the GHKL (DNA Gyrase, Hsp90, Histidine Kinase, MutL) superfamily. The 8 potent molecules are:

- Specific towards tested HK (WalK, PhoR and ResE)
- Inactive towards Ser/Thr kinase (IreK)
- Inactive towards DNA gyrase
- No hemolytical activity

dioxane/H₂O or DMF/H₂O or DMF, 70-90°C. **Scheme 1:** Synthesis of thiophene and furanes derivatives.

Reagents and conditions: Pd(PPh₃)₄ or PdCl₂(PPh₃)₂, Na₂CO₃ or K₂CO₃ or Cs₂CO₃, Toluene/EtOH or 1,4-

$$\langle r \rangle$$
 R_1 R_1

11d $R_1 = OH$; $R_2 = H$ **11e** $R_1 = H$; $R_2 = OH$

Reagents and conditions: i) Pd/C, NaBH_{4.} MeOH, 0°C to r.t., 30 min; ii) conc. HCl, THF, 0°C, 1h

Scheme 2: Synthesis of hydrochloride salts 11d and 11e.

All the derivatives were characterized by FT-IR, ¹H, ¹³C NMR, UPLC and HRMS.

→ H₂N / 35 - 88 % **6d** $R_1 = OH$; $R_2 = H$ **10d** $R_1 = OH$; $R_2 = H$ **10e** $R_1 = H$; $R_2 = OH$ **6e** $R_1 = H$; $R_2 = OH$

IV. CONCLUSION

Reduction of the most potent i) Nitro reduction compounds to experiment SAR




Figure 1: Structures of molecules 6d and 6e.

6d exhibits adjuvant activity in presence of antibiotics whereas **6e** showed antibacterial activity.

Table 1. IC_{50} values against histidine kinase PhoR, ResE and WalK; Ser/Thr kinase IreK and DNA-gyrase for compounds 6d, 6e and 11d.

Compounds	PhoR (µM)	ResE (µM)	WalK (µM)	IreK (µM)	DNA- gyrase (µM)
6d	122.6	124.3	196.9	> 800	> 400
6e	13.11	89.36	52.81	> 800	> 800
11d	50.53	/	/	/	/

In this work, we have designed and synthesized a series of 24 molecules with thiophene and furane ring by Suzuki-Miyaura coupling. On the other hand, two hydrochloride salts of nitrothiophene derivatives were synthesized to increase solubility, stability and therefore biodisponibility. All compounds were characterized by ¹H and ¹³C NMR and analyzed by LC-MS and HRMS. Two of them (**6d** and **6e**) exhibit significant inhibition of multiple HK and exhibited broad-spectrum antimicrobial activity. Moreover they do not inhibit the others GHKL superfamily proteins in addition to not hydrolyzing sheep red blood cells. More soluble hydrochloride salts of first designed amines (6a-8c) do not improve histidine kinase inhibition. The compounds were also evaluated as adjuvant against Escherichia coli extended spectrum β-lactamase (ESBL) and Methicillin resistant Staphylococcus aureus (MRSA). From this latter, derivative 6d showed adjuvant properties because of its tendency to restore antibacterial activity in presence of antibiotics on resistant bacteria.

REFERENCES

[1] Zschiedrich et al., J. Mol. Biol., 2016, 19, 3752–3775

[2] Bem et al., Chem. Biol., 2015, 10, 213-224

[3] Skedelj et al., J. Med. Chem., 2011, 44, 915-929

[4] Boibessot et al., J. Med. Chem., 2016, 59, 8830-8847 [5] Millet et al., J. Med. Chem., 2016, 59, 8276-8292

ACKNOWLEDMENTS

The author would like thank the Région Occitanie, the University of Nîmes, Miyanou ROSALES-HURTADO, Dr. Thibaut BOIBESSOT, Pr. Hendrik SZURMANT (USA) and Pr. Jean Philippe LAVIGNE (CHU Nîmes).